| HOME >> BIOLOGY >> TECHNOLOGY |
Restructuring
charges 1,013 2,228 12,252 8,240
Gain on sale of
fixed assets (6,459) - (6,459) -
Gain on sale of
assets held for sale - - (1,826) -
Total operating
expenses 7,749 24,734 55,993 108,577
Operating income
(loss) 21,412 (14,663) (3,726) (84,141)
Other expense, net (7,323) (6,416) (18,136) (14,542)
Income (loss)
before income
tax expense $14,089 $(21,079) $(21,862) $(98,683)
Income tax expense - - - -
Net income
(loss) $14,089 $(21,079) $(21,862) $(98,683)
Net income (loss) per
common and potential
common share:
Basic $0.30 $(0.45) $(0.47) $(2.13)
Diluted $0.28 $(0.45) $(0.47) $(2.13)
Weighted average common
and potential common
shares outstanding:
Basic 46,841 46,435 46,729 46,329
Diluted 52,396 46,435 46,729 46,329
NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
September 30, December 31,
2007 2006
Cash, cash equivalents and marketable
investment securities $302,229 $146,152
Current restricted cash and cash equivalents 16,246 21,921
Account r
'/>"/>
| SOURCE NPS Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |